Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia

Current Topics in Microbiology and Immunology

Volumn 313, Issue , 2007, Pages 145-156

  Lo Coco, F ^a   Ammatuna, E ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CD33 ANTIBODY; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TIOGUANINE; UNCLASSIFIED DRUG; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; GENE AMPLIFICATION; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL EXPERT; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SALVAGE THERAPY; STANDARDIZATION; TREATMENT RESPONSE; GENETICS; METHODOLOGY; MONITORING; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 33846979529     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-34594-7_9     Document Type: Review

References (51)

1. Alcalay M, Zangrilli D, Fagioli M, et al (1992) Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 89:4840-4844
2. Asou N, Adachi K, Tamura J, et al (1998) Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 16:78-85
3. Avvisati G (1999) Event-free survival (EFS) duration in newly diagnosed acute promyelocytic leukemia (APL) is favorably influenced by induction treatment with idarubicin alone: final results of the GIMEMA randomised study LAP0389 comparing IDA vs IDA+ARA-C in newly diagnosed APL. Blood 94 Suppl 1:505a
4. Avvisati G, Mandelli F, Petti MC, et al (1990) Idarubicin (4-demethoxidaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia. A pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 44:257-260
5. Barbui T, Finazzi G, Falanga A (1998) The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 91:3093-3102
6. Bennett JM, Catowsky D, Daniel MT, et al (1976) Proposal for the classification of the acute leukemias. Br J Haematol 33:451-458
7. Bennett JM, Catowsky D, Daniel MT, et al (1980) A variant form of hypergranular promyelocytic leukemia. Br J Haematol 44:169-170
8. Bernard J, Weil M, Boiron M, et al (1973) Acute promyelocytic leukemia. Results of treatment with daunorubicin. Blood 41:489-496
9. Burnett AK, Grimwade D, Solomon E, et al (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood 93:4131-4134
10. Candoni A, Damiani D, Michelutti A, et al (2003) Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. Eur J Haematol 71:1-8
11. Chen SJ, Wang ZY, Chen Z (1995) Acute promyelocytic leukaemia: from clinic to molecular biology. Stem Cells 13:22-31
12. Cheson BD, Bennett JM, Kopecky KJ, et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649
13. Diverio D, Pandolfi PP, Biondi A, et al (1993) Absence of RT-PCR detectable residual disease in acute promyelocytic leukemia in long termremission. Blood 85:3556-3559
14. Diverio D, Rossi V, Avvisati G, et al (1998) Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92:784-789
15. Estey E, Thall PF, Mehta K, et al (1996) Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 87:3650-3654
16. Estey EH, Giles FJ, Beran M, et al (2002) Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99:4222-4224
17. Falini B, Flenghi L, Fagioli M, et al (1997) Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with themonoclonal antibody PG-M3 (Anti-PML). Blood 90:4046-4053
18. Fenaux P, Chomienne C, Degos L (1997) Acute promyelocytic leukaemia: biology and treatment. Semin Oncol 24:92-102
19. Fenaux P, Chastang C, Chevret S, et al (1999) A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukaemia. Blood 94:1192-1200
20. Gallagher RE, Yeap BY, Bi W, et al (2003) Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 101:2521-2528
21. Gomis F, Sanz J, Sempere A, et al (2004) Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. Ann Hematol 83:687-690
22. Grignani F, Fagioli M, Alcalay M, et al (1994) Acute promyelocytic leukaemia: from genetics to treatment. Blood 83:10-25
23. Grimwade D (1999) The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 106:591-613
24. Grimwade D, Lo-Coco F (2002) Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 16:1959-1973
25. Grimwade D, Howe K, Langabeer S, et al (1996) Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 10:61-66
26. Guglielmi C, Martelli MP, Diverio D, et al (1998) Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 102:1035-1041
27. Jurcic JG, Nimer SD, Scheinberg DA, et al (2001) Prognostic significance of minimal residual disease detection and PML/RARα isoform type: long term follow-up in acute promyelocytic leukaemia. Blood 98:2651-2656
28. Lengfelder E, Reichert A, Schoch C, et al (2000) Double induction strategy including highdose cytarabine in combination with all-trans retinoic acid: effects inpatients with newly diagnosed acute promyelocytic leukemia German AML Cooperative Group. Leukemia 14:1362-1370
29. Lo-Coco F, Diverio D, Avvisati G, et al (1999a) Therapy of molecular relapse in acute promyelocytic leukaemia. Blood 94:2225-2229
30. Lo-Coco F, Diverio D, Falini B, et al (1999b) Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 94:12-22
31. Mandelli F, Diverio D, Avvisati G, et al (1997) Molecular remission in PML/RARa positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90:1014-1021
32. Marty M, Ganem G, Fischer J, et al (1984) Leucémie aigue promyélocitaire: étude retrospective de 119 malades traités par daunorubicine. Nouv Rev Fr Hematol 26:371-378
33. McKenna RW, Parkin J, Bloomfield CD, et al (1982) Acute promyelocytic leukemia a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol 50:201-214
34. Miller WH Jr, Kakizuka A, Frankel SR, et al (1992) Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 89:2694-2698
35. Paietta E (2003) Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16:369-385
36. Paietta E, Andersen J, Racevskis J, et al (1994) Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 8:968-973
37. Pandolfi PP, Alcalay A, Fagioli M, et al (1992) Genomic variability and alternative splicing generate multiple PML-RARα transcripts that encode aberrant PML proteins and PML-RARα isoforms in acute promyelocytic leukemia. EMBO J 11:1397-1407
38. Reiter A, Lengfelder E, Grimwade D (2004) Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Acta Haematol 112:55-67
39. Samoszuk MK, Tynan W, Sallash G, et al (1998) An immunofluorescent assay for acute promyelocytic leukemia. Am J Clin Pathol 109:205-210
40. Sanz M, Martin G, Gonzalez M, et al (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103:1237-1243
41. Sanz MA, Jarque I, Martin G, et al (1988) Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 61:7-13
42. Sanz MA, Martin G, Rayon C, et al (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa positive acute promyelocytic leukemia. Blood 94:3015-3021
43. Sanz MA, Lo-Coco F, Martín G, et al (2000) Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253
44. Sanz MA, Tallman M, Lo-Coco F (2005) Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 105:3019-3025
45. Seale JR, Varma S, Swirsky DM, et al (1996) Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. Br J Haematol 95:95-101
46. Shen ZX, Shi ZZ, Fang J, et al (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101:5328-5335
47. Tallman MS, Hakimian D, Snower D, et al (1993) Basophilic differentiation in acute promyelocytic leukemia. Leukemia 7:521-526
48. Tallman MS, Andersen JW, Schiffer CA, et al (2002) All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302
49. van Dongen JJ, Macintyre EA, Gabert JA, et al (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13:1901-1928
50. Villamor N, Costa D, Aymerich M, et al (2000) Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. Am J Clin Pathol 114:786-792
51. Warrell RP Jr (1996) Pathogenesis and management of acute promyelocytic leukaemia. Annu Rev Med 47:555-565